These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 17433787)

  • 1. A critical evaluation of serologic markers for inflammatory bowel disease.
    Austin GL; Herfarth HH; Sandler RS
    Clin Gastroenterol Hepatol; 2007 May; 5(5):545-7. PubMed ID: 17433787
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of serologic markers as a screening tool in inflammatory bowel disease compared with elevated erythrocyte sedimentation rate and anemia.
    Sabery N; Bass D
    Pediatrics; 2007 Jan; 119(1):e193-9. PubMed ID: 17158948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serologic markers in inflammatory bowel disease: tools for better diagnosis and disease stratification.
    Dotan I
    Expert Rev Gastroenterol Hepatol; 2007 Dec; 1(2):265-74. PubMed ID: 19072419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of serological and genetic markers in inflammatory bowel disease; strength and weakness of the studies.
    Peña AS
    Rev Esp Enferm Dig; 2003 Nov; 95(11):752-4, 749-51. PubMed ID: 14640872
    [No Abstract]   [Full Text] [Related]  

  • 5. The entire predictive value of the prometheus IBD sgi diagnostic product may be due to the three least expensive and most available components.
    Shirts B; von Roon AC; Tebo AE
    Am J Gastroenterol; 2012 Nov; 107(11):1760-1. PubMed ID: 23160303
    [No Abstract]   [Full Text] [Related]  

  • 6. Can serologic markers help determine prognosis and guide therapy?
    Dubinsky M
    Dig Dis; 2010; 28(3):424-8. PubMed ID: 20926867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re: marker of inflammatory bowel disease.
    Srinivasan R; Colman RW
    Am J Gastroenterol; 2000 Jul; 95(7):1849-50. PubMed ID: 10926011
    [No Abstract]   [Full Text] [Related]  

  • 8. Diagnostic value of serological assays in pediatric inflammatory bowel disorders.
    Mainardi E; Villanacci V; Bassotti G; Liserre B; Rossi E; Incardona P; Falchetti D; Tonegatti L; Montanelli A; Barabino A; Coccia C; Gambini C
    Digestion; 2007; 75(4):210-4. PubMed ID: 17952008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positive and negative predictive values: use of inflammatory bowel disease serologic markers.
    Austin GL; Shaheen NJ; Sandler RS
    Am J Gastroenterol; 2006 Mar; 101(3):413-6. PubMed ID: 16542272
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluation of disease activity markers in dogs with idiopathic inflammatory bowel disease.
    McCann TM; Ridyard AE; Else RW; Simpson JW
    J Small Anim Pract; 2007 Nov; 48(11):620-5. PubMed ID: 17608662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Carbonyl groups content in serum proteins as an indicator of disease activity in children with inflammatory bowel diseases and its dependence on the other markers of inflammatory process].
    Krzesiek E; Pytrus T; Kosmowska A; Iwańczak B
    Pol Merkur Lekarski; 2008 Dec; 25(150):455-9. PubMed ID: 19205373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease.
    Canani RB; Terrin G; Rapacciuolo L; Miele E; Siani MC; Puzone C; Cosenza L; Staiano A; Troncone R
    Dig Liver Dis; 2008 Jul; 40(7):547-53. PubMed ID: 18358796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Markers that differentiate early from late IBD.
    Huang C; Kugathasan S
    Dig Dis; 2012; 30(4):380-2. PubMed ID: 22796800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accuracy of four fecal assays in the diagnosis of colitis.
    Schoepfer AM; Trummler M; Seeholzer P; Criblez DH; Seibold F
    Dis Colon Rectum; 2007 Oct; 50(10):1697-706. PubMed ID: 17762964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study.
    Henriksen M; Jahnsen J; Lygren I; Stray N; Sauar J; Vatn MH; Moum B;
    Gut; 2008 Nov; 57(11):1518-23. PubMed ID: 18566104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Biological markers of activity in chronic inflammatory bowel disease].
    Sánchez Lombraña J; Palacio MA; Carbajal C; Vivas S; Pérez R; Rodrigo L
    Rev Esp Enferm Dig; 1997 Nov; 89(11):855-8. PubMed ID: 9580203
    [No Abstract]   [Full Text] [Related]  

  • 17. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease.
    Gisbert JP; McNicholl AG
    Dig Liver Dis; 2009 Jan; 41(1):56-66. PubMed ID: 18602356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum S100A12 as a new marker for inflammatory bowel disease and its relationship with disease activity.
    Brinar M; Cleynen I; Coopmans T; Van Assche G; Rutgeerts P; Vermeire S
    Gut; 2010 Dec; 59(12):1728-9; author reply 1729-30. PubMed ID: 20732921
    [No Abstract]   [Full Text] [Related]  

  • 19. [Measurement of calprotectin in faeces].
    Jahnsen J; Røseth AG; Aadland E
    Tidsskr Nor Laegeforen; 2009 Apr; 129(8):743-5. PubMed ID: 19373299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Serological markers in inflammatory bowel disease: differences among populations and limitations of their application].
    Barahona-Garrido J; Hernández-Calleros J; Sarti HM; Cabiedes J; Yamamoto-Furusho JK
    Gastroenterol Hepatol; 2009 May; 32(5):380-1. PubMed ID: 19457592
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.